Moreover, the number of patients with germline BRCA mutations who can benefit from PARP inhibitors, currently the only approved indication for targeted therapy in pancreatic cancer, might have been underestimated in this study because two other patients with BRCA2 mutations (Tier I and Tier II, respectively) did not undergo germline testing. The gene discussed is BRCA2; the disease is pancreatic neoplasm.